MA26451A1 - Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. - Google Patents
Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.Info
- Publication number
- MA26451A1 MA26451A1 MA24877A MA24877A MA26451A1 MA 26451 A1 MA26451 A1 MA 26451A1 MA 24877 A MA24877 A MA 24877A MA 24877 A MA24877 A MA 24877A MA 26451 A1 MA26451 A1 MA 26451A1
- Authority
- MA
- Morocco
- Prior art keywords
- apo
- amides
- preparation
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3230796P | 1996-11-27 | 1996-11-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA26451A1 true MA26451A1 (fr) | 2004-12-20 |
Family
ID=21864233
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA24877A MA26451A1 (fr) | 1996-11-27 | 1997-11-26 | Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US6121283A (fr) |
| EP (1) | EP0944602A1 (fr) |
| JP (1) | JP3270764B2 (fr) |
| KR (1) | KR100334567B1 (fr) |
| CN (2) | CN1238764A (fr) |
| AP (1) | AP804A (fr) |
| AR (1) | AR010309A1 (fr) |
| AU (1) | AU716151B2 (fr) |
| BG (2) | BG103434A (fr) |
| BR (1) | BR9714364A (fr) |
| CA (1) | CA2272719C (fr) |
| CZ (1) | CZ292160B6 (fr) |
| DZ (1) | DZ2358A1 (fr) |
| EA (1) | EA001539B1 (fr) |
| GT (1) | GT199700122A (fr) |
| HN (1) | HN1997000144A (fr) |
| HR (1) | HRP970642A2 (fr) |
| ID (1) | ID18995A (fr) |
| IL (1) | IL129744A0 (fr) |
| IS (1) | IS5040A (fr) |
| MA (1) | MA26451A1 (fr) |
| NO (1) | NO312760B1 (fr) |
| NZ (1) | NZ335162A (fr) |
| OA (1) | OA11050A (fr) |
| PA (1) | PA8441601A1 (fr) |
| PE (1) | PE17199A1 (fr) |
| SK (1) | SK65499A3 (fr) |
| TN (1) | TNSN97193A1 (fr) |
| TR (1) | TR199901180T2 (fr) |
| TW (1) | TW502023B (fr) |
| UY (1) | UY24789A1 (fr) |
| WO (1) | WO1998023593A1 (fr) |
| YU (1) | YU23499A (fr) |
| ZA (1) | ZA9710641B (fr) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| ATE233734T1 (de) * | 1995-06-07 | 2003-03-15 | Pfizer | Biphenyl-2-carbonsäure-tetrahydro-isochinolin-6 yl amid derivate, deren hestellung und deren verwendung als inhibitoren des mikrosomalen triglycerid-transfer-proteins und/oder der apolipoprotein b (apo b) sekretion |
| GB9708805D0 (en) | 1997-05-01 | 1997-06-25 | Smithkline Beecham Plc | Compounds |
| US5968950A (en) * | 1997-06-23 | 1999-10-19 | Pfizer Inc | Apo B-secretion/MTP inhibitor hydrochloride salt |
| GB9810876D0 (en) | 1998-05-20 | 1998-07-22 | Smithkline Beecham Plc | Compounds |
| US6288234B1 (en) | 1998-06-08 | 2001-09-11 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| SK4782001A3 (en) | 1998-10-08 | 2001-11-06 | Smithkline Beecham Plc | Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents) |
| GB9826412D0 (en) | 1998-12-03 | 1999-01-27 | Glaxo Group Ltd | Chemical compounds |
| IL143946A0 (en) * | 1998-12-23 | 2002-04-21 | Searle Llc | Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein for cardiovascular indications |
| CN1342091A (zh) * | 1998-12-23 | 2002-03-27 | G.D.瑟尔有限公司 | 心血管指征的联合用药 |
| DE19929031A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und Lipidsenkern und ihre Verwendung in Arzneimitteln |
| DE19929012A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und stoffwechselbeeinflussenden Wirkstoffen und ihre Verwendung in Arzneimitteln |
| DE19929065A1 (de) * | 1999-06-25 | 2000-12-28 | Bayer Ag | Kombination von MTP-Inhibitoren und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| WO2001005767A1 (fr) * | 1999-07-20 | 2001-01-25 | Novartis Ag | Composes organiques |
| IL139450A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Methods of administering apo b-secretion/mtp inhibitors |
| IL139449A0 (en) * | 1999-11-10 | 2001-11-25 | Pfizer Prod Inc | Use of apo b secretion/mtp inhibitors |
| CA2324800A1 (fr) * | 1999-11-10 | 2001-05-10 | Mary Anne Hickman | Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp |
| CA2324801A1 (fr) * | 1999-11-10 | 2001-05-10 | Andrew Gordon Swick | Utilisation d'inhibiteurs de secretion d'apo b et/ou de mtp et d'agents contre l'obesite |
| ES2240420T3 (es) | 2000-01-18 | 2005-10-16 | Novartis Ag | Carboxamidas utiles como inhibidores de la proteina de transferencia de trigliceridos microsomicos y de la secrecion de apolipoproteina b. |
| AU2001260113B2 (en) | 2000-03-14 | 2006-04-06 | Actelion Pharmaceuticals Ltd. | 1,2,3,4-tetrahydroisoquinoline derivatives |
| AU2001262185A1 (en) * | 2000-04-10 | 2001-10-23 | Novartis Ag | Substituted (hetero)aryl carboxamide derivatives as microsomal triglyceride transfer protein (mtp) and apolipoprotein b (apo b) secretion |
| GB0013346D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| GB0013383D0 (en) * | 2000-06-01 | 2000-07-26 | Glaxo Group Ltd | Therapeutic benzamide derivatives |
| AU2001277728A1 (en) * | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Biphenylcarboxamidoisoindoline compounds, processes for the preparation of the same and intermediates for the synthesis thereof |
| AU2001277727A1 (en) * | 2000-08-10 | 2002-02-25 | Tanabe Seiyaku Co., Ltd. | Benzoylaminoisoindoline compounds, processes for the preparation of the same andintermediates for the synthesis thereof |
| KR20030029871A (ko) * | 2000-09-01 | 2003-04-16 | 상꾜 가부시키가이샤 | 의약 조성물 |
| JO2654B1 (en) | 2000-09-04 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Multiple aryl caroxa amides are useful as lipid - lowering agents |
| IL155196A0 (en) * | 2000-10-05 | 2003-11-23 | Fujisawa Pharmaceutical Co | Benzamide derivatives and pharmaceutical compositions containing the same |
| JO2409B1 (en) | 2000-11-21 | 2007-06-17 | شركة جانسين فارماسوتيكا ان. في | Second-phenyl carboxy amides are useful as lipid-lowering agents |
| WO2002090347A1 (fr) * | 2001-04-30 | 2002-11-14 | Fujisawa Pharmaceutical Co., Ltd. | Composes biarylcarboxamide comme inhibiteurs d'apolipoproteine b |
| EP1404300B1 (fr) * | 2001-06-22 | 2009-09-30 | Pfizer Products Inc. | Compositions pharmaceutiques de dispersions de medicaments et de polymeres neutres |
| JP4139325B2 (ja) | 2001-06-28 | 2008-08-27 | ファイザー・プロダクツ・インク | ミクロソーム・トリグリセリド・トランスファータンパク質（ｍｔｐ）及び／又はアポリポタンパク質ｂ（ａｐｏｂ）分泌の阻害剤としてのトリアミド置換インドール、ベンゾフラン及びベンゾチオフェン |
| AU2002322585A1 (en) * | 2001-07-20 | 2003-03-03 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| WO2003013516A1 (fr) * | 2001-08-10 | 2003-02-20 | Adipogenix, Inc. | Composes servant a moduler l'accumulation des graisses |
| CA2468716A1 (fr) * | 2001-11-28 | 2003-06-05 | Fujisawa Pharmaceutical Co., Ltd. | Composes d'amide heterocycliques en tant qu'inhibiteurs de l'apolipoproteine b |
| CA2472028C (fr) * | 2002-02-01 | 2010-03-30 | Pfizer Products Inc. | Procede de fabrication de dispersions medicamenteuses amorphes solides homogenes sechees par pulverisation au moyen d'un appareil de sechage par pulverisation modifie |
| SG165154A1 (en) * | 2002-02-28 | 2010-10-28 | Japan Tobacco Inc | Ester compound and medical use thereof |
| JP4542341B2 (ja) * | 2002-03-13 | 2010-09-15 | ザ ユニバーシティ オブ テネシー リサーチ ファウンデイション | 置換テトラヒドロイソキノリン化合物、調製方法、およびその使用 |
| WO2004039795A2 (fr) * | 2002-10-29 | 2004-05-13 | Fujisawa Pharmaceutical Co., Ltd. | Composes amide |
| AU2003286311A1 (en) * | 2002-12-20 | 2004-07-14 | Pfizer Products Inc. | Microsomal triglyceride transfer protein inhibitors |
| WO2004056775A1 (fr) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Inhibiteurs de proteine de transfert de triglyceride microsomale |
| MXPA05009976A (es) | 2003-03-17 | 2005-11-04 | Japan Tobacco Inc | Metodo para incrementar la biodisponibilidad oral del 2-metilpropantioato de s-[2-([[1- 2-etilbutil) ciclohexil] carbonil] amino) fenilo]. |
| EP1669345A4 (fr) * | 2003-08-29 | 2008-02-20 | Japan Tobacco Inc | Derive d'ester et utilisation medicale de celui-ci |
| WO2005118548A1 (fr) | 2004-03-01 | 2005-12-15 | Actelion Pharmaceuticals Ltd | Derives de 1,2,3,4-tétrahydroisoquinoléine substitués |
| US7932268B2 (en) | 2004-03-05 | 2011-04-26 | The Trustees Of The University Of Pennsylvania | Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side effects |
| US7262318B2 (en) * | 2004-03-10 | 2007-08-28 | Pfizer, Inc. | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20050288340A1 (en) * | 2004-06-29 | 2005-12-29 | Pfizer Inc | Substituted heteroaryl- and phenylsulfamoyl compounds |
| US20060030623A1 (en) * | 2004-07-16 | 2006-02-09 | Noboru Furukawa | Agent for the treatment or prevention of diabetes, obesity or arteriosclerosis |
| US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
| KR20070072888A (ko) * | 2004-10-25 | 2007-07-06 | 니뽄 다바코 산교 가부시키가이샤 | 용해성 및 안정성이 개선된 고형 제제 및 그의 제조 방법 |
| WO2006050999A2 (fr) * | 2004-11-15 | 2006-05-18 | Obe Therapy Biotechnology S.A.S | Compositions pharmaceutiques et procedes de reduction de la graisse corporelle |
| JP2006249022A (ja) | 2005-03-11 | 2006-09-21 | Sumitomo Chemical Co Ltd | ４−（２−メチルフェニル）ベンゾトリフルオライドの製造方法 |
| CA2605510C (fr) | 2005-04-19 | 2013-12-24 | Surface Logix, Inc. | Inhibiteurs des secretions microsomales des apo-b et des proteines de transfert des triglycerides |
| CA2609783A1 (fr) * | 2005-05-27 | 2006-12-07 | Pfizer Products Inc. | Polytherapie pour le traitement de l'obesite ou le maintien du poids apres une perte ponderale |
| US7741317B2 (en) | 2005-10-21 | 2010-06-22 | Bristol-Myers Squibb Company | LXR modulators |
| US7888376B2 (en) | 2005-11-23 | 2011-02-15 | Bristol-Myers Squibb Company | Heterocyclic CETP inhibitors |
| US8383660B2 (en) | 2006-03-10 | 2013-02-26 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| US7919506B2 (en) | 2006-03-10 | 2011-04-05 | Pfizer Inc. | Dibenzyl amine compounds and derivatives |
| EP1998620B1 (fr) * | 2006-03-10 | 2011-01-12 | Neurogen Corporation | Piperazinyl-oxoalkyl-tetrahydroisoquinoleines et analogues apparentes |
| CA2649045C (fr) | 2006-04-03 | 2019-06-11 | Santaris Pharma A/S | Composition pharmaceutique renfermant des oligonucleotides antisens anti-mirna |
| EP3502255A1 (fr) * | 2006-04-03 | 2019-06-26 | Roche Innovation Center Copenhagen A/S | Composition pharmaceutique |
| US20090042835A1 (en) * | 2006-06-02 | 2009-02-12 | Davis Roger A | Compositions and methods for ameliorating hyperlipidemia |
| CA2654183A1 (fr) * | 2006-06-02 | 2007-12-13 | San Diego State University Research Foundation | Compositions et procedes pour ameliorer l'hyperlipidemie |
| MX2009003729A (es) * | 2006-10-09 | 2009-04-22 | Santaris Pharma As | Copuestos antagonistas de acido ribonucleico para la modulacion de proproteina convertasa subtilisina/kexina tipo 9a. |
| TW200831497A (en) * | 2006-10-12 | 2008-08-01 | Epix Delaware Inc | Carboxamide compounds and their use |
| EP2076487B1 (fr) * | 2006-10-24 | 2010-05-26 | Janssen Pharmaceutica N.V. | Derives acide tetrahydro-naphtalene-1-carboxylique inhibant le mtp |
| JO2653B1 (en) | 2006-10-24 | 2012-06-17 | شركة جانسين فارماسوتيكا ان. في | Tetrahydroflavin 1-carboxylic acid substituted with pyridine or pyrazine inhibit MTB |
| CN101663262B (zh) | 2006-12-01 | 2014-03-26 | 百时美施贵宝公司 | 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物 |
| WO2008075949A1 (fr) * | 2006-12-20 | 2008-06-26 | Friesland Brands B.V. | Modulation de l'expression génique d'une protéine microsomale de transfert des triglycérides (mtp ou mttp) au moyen de microorganismes alimentaires ingérés/de qualité alimentaire |
| EP2120927A1 (fr) * | 2006-12-21 | 2009-11-25 | Aegerion Pharmaceuticals, Inc. | Procédés de traitement de l'obésité à l'aide d'une combinaison comprenant un inhibiteur de mtp et un inhibiteur de l'absorption du cholestérol |
| WO2008113830A1 (fr) * | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Composés arn antagonistes pour l'inhibition de l'expression de l'apo-b100 |
| DK2149605T3 (da) * | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
| JP2010531364A (ja) * | 2007-06-25 | 2010-09-24 | ニューロジェン・コーポレーション | ピペラジニルオキソアルキルテトラヒドロ−β−カルボリンおよび関連類似体 |
| JP2010537958A (ja) * | 2007-08-30 | 2010-12-09 | サンタリス ファーマ アー／エス | Ｆａｂｐ４／ａｐ２を調節するためのｒｎａアンタゴニスト化合物 |
| CA2701547C (fr) * | 2007-10-04 | 2020-03-10 | Santaris Pharma A/S | Oligonucleotiques qui ciblent et inhibent les micro arn |
| CA2707549A1 (fr) | 2007-12-03 | 2009-06-11 | Itzik Harosh | Inhibiteurs boropeptidiques de l'enterokinase et leurs utilisations dans le traitement de l'obesite, de la surcharge ponderale et/ou des maladies associees avec un metabolisme anormal des lipides |
| AU2008335135A1 (en) | 2007-12-11 | 2009-06-18 | Cytopathfinder, Inc. | Carboxamide compounds and their use as chemokine receptor agonists |
| US20090197947A1 (en) * | 2008-02-01 | 2009-08-06 | The Research Foundation Of State University Of New York | Medicaments and methods for lowering plasma lipid levels and screening drugs |
| CA2717792A1 (fr) * | 2008-03-07 | 2009-09-11 | Santaris Pharma A/S | Compositions pharmaceutiques pour le traitement de maladies associees aux microarn |
| WO2010012667A1 (fr) | 2008-08-01 | 2010-02-04 | Santaris Pharma A/S | Modulation à médiation par micro-arn de facteurs stimulateurs de colonies |
| EP2421970B1 (fr) * | 2009-04-24 | 2016-09-07 | Roche Innovation Center Copenhagen A/S | Compositions pharmaceutiques pour le traitement de patients souffrant du vhc ne réagissant pas aux interférons |
| US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
| CA2909442A1 (fr) | 2013-04-17 | 2014-10-23 | Pfizer Inc. | Derives de n-piperidin-3-ylbenzamide dans le traitement des maladies cardiovasculaires |
| KR101931089B1 (ko) | 2013-06-27 | 2019-03-14 | 로슈 이노베이션 센터 코펜하겐 에이/에스 | Pcsk９ 를 표적화하는 안티센스 올리고머 및 접합체 |
| US9856478B2 (en) | 2013-10-30 | 2018-01-02 | Trustees Of Dartmouth College | Method for selectively inhibiting ACAT1 in the treatment of obesity, metabolic syndrome, and atherosclerosis |
| WO2016055901A1 (fr) | 2014-10-08 | 2016-04-14 | Pfizer Inc. | Composés d'amide substitué |
| EP3209299A4 (fr) * | 2014-10-22 | 2018-04-04 | The Board of Regents of The University of Texas System | Inhibiteurs à petites molécules ciblant le récepteur du domaine discoïdine 1 et ses utilisations |
| EP3911648A4 (fr) | 2019-01-18 | 2022-10-26 | Astrazeneca AB | Inhibiteurs de pcsk9 et leurs procédés d'utilisation |
| CN113292493A (zh) * | 2021-06-23 | 2021-08-24 | 上海立科化学科技有限公司 | 5,7-二氯-1,2,3,4-四氢异喹啉的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4022900A (en) * | 1970-09-09 | 1977-05-10 | Marion Laboratories, Inc. | Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents |
| US5595872A (en) * | 1992-03-06 | 1997-01-21 | Bristol-Myers Squibb Company | Nucleic acids encoding microsomal trigyceride transfer protein |
| US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
| WO1996040640A1 (fr) * | 1995-06-07 | 1996-12-19 | Pfizer Inc. | DERIVES DE BIPHENYL-2-ACIDE CARBOXYLIQUE-TETRAHYDRO-ISOQUINOLEINE-6-YL AMIDES, PREPARATION DE CES AMIDES ET UTILISATION EN TANT QU'INHIBITEURS DE LA PROTEINE DE TRANSFERT DE TRIGLYCERIDE MICROSOMAL ET/OU DE LA SECRETION D'APOLIPOPROTEINES B (Apo B) |
-
1997
- 1997-11-03 CA CA002272719A patent/CA2272719C/fr not_active Expired - Fee Related
- 1997-11-03 BR BR9714364A patent/BR9714364A/pt not_active Application Discontinuation
- 1997-11-03 CN CN97180033A patent/CN1238764A/zh active Pending
- 1997-11-03 WO PCT/IB1997/001368 patent/WO1998023593A1/fr not_active Application Discontinuation
- 1997-11-03 YU YU23499A patent/YU23499A/sh unknown
- 1997-11-03 TR TR1999/01180T patent/TR199901180T2/xx unknown
- 1997-11-03 JP JP52446498A patent/JP3270764B2/ja not_active Expired - Fee Related
- 1997-11-03 AU AU46347/97A patent/AU716151B2/en not_active Ceased
- 1997-11-03 NZ NZ335162A patent/NZ335162A/xx unknown
- 1997-11-03 SK SK654-99A patent/SK65499A3/sk unknown
- 1997-11-03 US US09/284,466 patent/US6121283A/en not_active Expired - Fee Related
- 1997-11-03 KR KR1019997004662A patent/KR100334567B1/ko not_active IP Right Cessation
- 1997-11-03 EA EA199900416A patent/EA001539B1/ru not_active IP Right Cessation
- 1997-11-03 EP EP97945048A patent/EP0944602A1/fr not_active Withdrawn
- 1997-11-03 IL IL12974497A patent/IL129744A0/xx unknown
- 1997-11-04 HN HN1997000144A patent/HN1997000144A/es unknown
- 1997-11-05 TW TW086116476A patent/TW502023B/zh not_active IP Right Cessation
- 1997-11-14 PA PA84416A patent/PA8441601A1/es unknown
- 1997-11-20 AP APAP/P/1997/001145A patent/AP804A/en active
- 1997-11-24 PE PE1997001062A patent/PE17199A1/es not_active Application Discontinuation
- 1997-11-25 GT GT199700122A patent/GT199700122A/es unknown
- 1997-11-25 UY UY24789A patent/UY24789A1/es not_active Application Discontinuation
- 1997-11-25 ID IDP973763A patent/ID18995A/id unknown
- 1997-11-26 MA MA24877A patent/MA26451A1/fr unknown
- 1997-11-26 ZA ZA9710641A patent/ZA9710641B/xx unknown
- 1997-11-26 AR ARP970105560A patent/AR010309A1/es unknown
- 1997-11-26 HR HR60/032,307A patent/HRP970642A2/hr not_active Application Discontinuation
- 1997-11-26 DZ DZ970208A patent/DZ2358A1/fr active
- 1997-11-26 TN TNTNSN97193A patent/TNSN97193A1/fr unknown
-
1999
- 1999-04-30 IS IS5040A patent/IS5040A/is unknown
- 1999-05-19 OA OA9900106A patent/OA11050A/en unknown
- 1999-05-26 NO NO19992525A patent/NO312760B1/no unknown
- 1999-05-26 BG BG103434A patent/BG103434A/xx unknown
- 1999-05-26 BG BG108830A patent/BG108830A/bg unknown
-
2002
- 2002-02-19 CN CN02105189A patent/CN1380289A/zh active Pending
- 2002-09-17 CZ CZ20023137A patent/CZ292160B6/cs not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA26451A1 (fr) | Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26687A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2780057B1 (fr) | Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26630A1 (fr) | 4-phenylpyperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26494A1 (fr) | Inhibiteurs de proteases nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2748026B1 (fr) | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent | |
| MA26424A1 (fr) | Derives de 6-phenylpyridyl-2-amine, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26415A1 (fr) | Composes heterocycliques, procede pour la preparation et compositions pharmaceutiques les contenant | |
| MA23866A1 (fr) | N-(indole-2-carbonyl)-glycinamides substitues, procede pour leur preparation et compositions les contenant | |
| MA26508A1 (fr) | Formulations pharmaceutiques contenant du variconazole, et procede pour leur preparation. | |
| FR2729951B1 (fr) | Nouveaux composes heterocycliques, procede pour leur preparation et compositions pharmaceutiques en contenant | |
| MA26559A1 (fr) | Derives de d-proline, procede pour leur preparation, compositions pharmaceutiques les contenant et leur utilisation | |
| MA26432A1 (fr) | Derives de 2-(2-oxo-ethylidene)-imidazolidine-4-one, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26433A1 (fr) | Derives de pyridylpyrrole, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26614A1 (fr) | Bicyclo [2.2.1] heptanes nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26622A1 (fr) | Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26443A1 (fr) | Aralkyl- et aralkylidene-lactames et -imides heterocycliques, procedes pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26438A1 (fr) | Derives 6,5-heterobicycliques substitues, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26439A1 (fr) | Derives d'indazole nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| FR2740136B1 (fr) | Derives d'indolin-2-one, procede pour leur preparation et les compositions pharmaceutiques les contenant | |
| FR2665453B1 (fr) | Polylactides purifies, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| MA26425A1 (fr) | Derives de lactames, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| MA26499A1 (fr) | Derives de tetrazole, procede pour leur preparation et compositions pharmaceutiques les contenant . | |
| MA26558A1 (fr) | Derives nouveaux de 6-0-methylerythromycine a, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| FR2751334B1 (fr) | Polysaccharides synthetiques, procede pour leur preparation et compositions pharmaceutiques les contenant |